Literature DB >> 17882724

A comparative study of hFIX expression mediated by rAAV8 and rAAV1 administrated intramuscularly.

Z Cao1, P Zheng, Y Lin.   

Abstract

BACKGROUND: Recombinant AAV serotype 8 (rAAV8) vector is relatively new for gene therapy. In this study, the hFIX expression mediated by rAAV8 injected intramuscularly was compared with that by rAAV1.
METHODS: rAAV8-hFIX or rAAV1-hFIX viruses were injected intramuscularly into two hind limbs of mice at doses of 5x10(10) gc and 2.5x10(12) gc (genome copy). The hFIX expression in the mouse plasma was detected by ELISA, APTT and Western blotting. The virus distribution was analyzed by immunohistochemical assay.
RESULTS: When the mice were infected with 5x10(10) gc virus, high levels of hFIX in the plasma of five rAAV8-hFIX virus-infected mice were detected 2 weeks after injection. A hFIX peak above 5000 ng/mL appeared between 2 and 6 weeks after injection. Relatively low levels of hFIX were detected in the plasma of rAAV1-hFIX virus-infected mice 2 weeks after injection. An hFIX peak above 3000 ng/mL appeared between 4 and 10 weeks after injection. However, much lower levels of hFIX were detected in mice infected with higher dose of rAAV8 virus. The hFIX in the mouse plasma was active biologically. The viruses were distributed mainly in the muscles of hind limbs. DISCUSSION: Gene expression mediated by rAAV8 was sooner and stronger than that by rAAV1 after intramuscular administration. Inhibition might have been triggered markedly by rAAV8 at high doses.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17882724     DOI: 10.1080/14653240701519004

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  2 in total

1.  Recombinant adeno-associated virus vectors in the treatment of rare diseases.

Authors:  Eric Hastie; R Jude Samulski
Journal:  Expert Opin Orphan Drugs       Date:  2015-05-15       Impact factor: 0.694

2.  Role of antigen-specific regulatory CD4+CD25+ T cells in tolerance induction after neonatal IP administration of AAV-hF.IX.

Authors:  Y Shi; R Falahati; J Zhang; L Flebbe-Rehwaldt; K M L Gaensler
Journal:  Gene Ther       Date:  2013-06-13       Impact factor: 5.250

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.